Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Medicine and Health Sciences
Repurposing Celecoxib As A Topical Antimicrobial Agent, Shankar Thangamani, Waleed Younis, Mohamed N. Seleem
Repurposing Celecoxib As A Topical Antimicrobial Agent, Shankar Thangamani, Waleed Younis, Mohamed N. Seleem
Department of Comparative Pathobiology Faculty Publications
There is an urgent need for new antibiotics and alternative strategies to combat multidrug-resistant bacterial pathogens, which are a growing clinical issue. Repurposing existing approved drugs with known pharmacology and toxicology is an alternative strategy to accelerate antimicrobial research and development. In this study, we show that celecoxib, a marketed inhibitor of cyclooxygenase-2, exhibits broad-spectrum antimicrobial activity against Gram-positive pathogens from a variety of genera, including Staphylococcus, Streptococcus, Listeria, Bacillus, and Mycobacterium, but not against Gram-negative pathogens. However, celecoxib is active against all of the Gram-negative bacteria tested, including strains of, Acinetobacter, and Pseudomonas, when …
Efficacy Of Short Novel Antimicrobial And Anti-Inflammatory Peptides In A Mouse Model Of Methicillin-Resistant Staphylococcus Aureus (Mrsa) Skin Infection, Mohamed F. Mohamed, Mohamed N. Seleem
Efficacy Of Short Novel Antimicrobial And Anti-Inflammatory Peptides In A Mouse Model Of Methicillin-Resistant Staphylococcus Aureus (Mrsa) Skin Infection, Mohamed F. Mohamed, Mohamed N. Seleem
Department of Comparative Pathobiology Faculty Publications
The therapeutic efficacy of two novel short antimicrobial and anti-inflammatory peptides (RR and RRIKA) was evaluated in a mouse model of staphylococcal skin infection. RR (2%) and RRIKA (2%) significantly reduced the bacterial counts and the levels of proinflammatory cytokines, tumor necrosis factor (TNF)-α, and interleukin (IL)-6, in methicillin-resistant Staphylococcus aureusUSA 300-0114 skin lesions. Furthermore, the combined therapy of RRIKA (1%) and lysostaphin (0.5%) had significantly higher antistaphylococcal and anti-inflammatory activity compared to monotherapy. This study supports the potential use of these peptides for topical treatment of methicillin-resistant Staphylococcus aureus skin infections.